Circulating tumor cell (CTC) assay to explore the role of circadian rhythm in prostate cancer metastasis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072962

Enrollment

Unknown

Registered

2023-06-28

Start date

2023-06-30

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCa(prostatic cancer)

Interventions

Prostate cancer with local lymph node metastasis:N/A

Prostate cancer with distant lymph node metastasis:N/A

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age of patients 50-85 years old; 2. Patients diagnosed with lymph node metastasis or distant metastatic prostate cancer; 3. The results of prostate puncture biopsy, radionuclide bone imaging and prostate MRI showed the characteristics of metastatic prostate cancer. 4. Sign informed consent;

Exclusion criteria

Exclusion criteria: 1. Patients who cannot understand the research process/do not have the intention to participate in this research project, and are unwilling or unable to provide medical records, examination reports and other relevant materials; 2. Clinically, patients with severe metabolic, immune, neurological, blood, digestive, cardiovascular and cerebrovascular diseases;

Design outcomes

Primary

Measure	Time frame
circulating tumor cell;androgen;prolactin;insulin;insulin;Adrenocorticotropic Hormone;prostaglandin;	—

Countries

China

Contacts

Public ContactBaoqing Sun

The First Affiliated Hospital of Guangzhou Medical University

sunbaoqing@vip.163.com+86 20 8306 2865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026